{"preliminary_commentary":{"by_channel":{"x_thread":2,"bluesky_thread":1},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build."},"free_build":{"available":false},"name":"NIAGARA","nct_id":"NCT03732677","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=niagara-nct03732677. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"NIAGARA","arms":[{"description":"Chemotherapy + Durvalumab","label":"Arm 1","type":"EXPERIMENTAL"},{"description":"Chemotherapy alone","label":"Arm 2","type":"ACTIVE_COMPARATOR"}],"collaborators":[],"completion_date":{"date":"2027-11-08","type":"ESTIMATED"},"conditions":["Muscle Invasive Bladder Cancer"],"enrollment":{"count":1063,"type":"ACTUAL"},"has_results":true,"interventions":[{"name":"Durvalumab","otherNames":[],"type":"DRUG"},{"name":"Cisplatin","otherNames":[],"type":"DRUG"},{"name":"Gemcitabine","otherNames":[],"type":"DRUG"}],"last_update":"2026-10-15","lead_sponsor":"AstraZeneca","official_title":"A Phase III, Randomized, Open-Label, Multi-Center, Global Study to Determine the Efficacy and Safety of Durvalumab in Combination With Gemcitabine+Cisplatin for Neoadjuvant Treatment Followed by Durvalumab Alone for Adjuvant Treatment in Patients With Muscle-Invasive Bladder Cancer.","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2024-04-29","type":"ACTUAL"},"primary_outcomes":[{"measure":"Pathologic Complete Response (pCR) Rates at Time of Cystectomy","timeFrame":"Up to 6 months"},{"measure":"Event-free Survival (EFS) Per Central Review Defined as Time From Randomization to Event","timeFrame":"Up to 48 months"}],"references":[{"citation":"Powles T, Catto JWF, Galsky MD, Al-Ahmadie H, Meeks JJ, Nishiyama H, Vu TQ, Antonuzzo L, Wiechno P, Atduev V, Kann AG, Kim TH, Suarez C, Chang CH, Roghmann F, Ozguroglu M, Eigl BJ, Oliveira N, Buchler T, Gadot M, Zakharia Y, Armstrong J, Gupta A, Hois S, van der Heijden MS; NIAGARA Investigators. Perioperative Durvalumab with Neoadjuvant Chemotherapy in Operable Bladder Cancer. N Engl J Med. 2024 Nov 14;391(19):1773-1786. doi: 10.1056/NEJMoa2408154. Epub 2024 Sep 15.","pmid":"39282910","type":"DERIVED"}],"start_date":{"date":"2018-11-16","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Durvalumab+ Gemcitabine/Cisplatin (Neoadjuvant Treatment) and Durvalumab (Adjuvant Treatment) in Patients With MIBC","url":"https://clinicaltrials.gov/study/NCT03732677"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/niagara-nct03732677"}